StreetAlpha.app
Home › Stocks › RXST

RxSight, Inc. (RXST)

Healthcare
$4.83
▼ −8.87%
LAST CLOSE · NOV 17

RxSight makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. It last closed at $4.83 on Nov 17, down 8.87% on the day. The average 12-month price target from 5 analysts is $6.45 (+33.5% from the last close), with a high of $8.00 and a low of $5.50. Analyst consensus is Hold, based on the latest ratings from 5 firms (1 buy, 3 hold, 1 sell).

AI Auto Pilots
Is RXST in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$121.8M
−14.3% vs a year ago
Net income
−$53.4M
−43.8% margin
EPS (diluted)
−$1.29
Free cash flow
$18.6M
15.3% margin
Valuation
Market cap
$202.5M
41.9M shares
P/E
–
No P/E while losing money
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$66.7M
At Sep 30
Shareholder equity
$254.9M
Shares outstanding
41.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $22.6M$22.6MFY2021FY2022: $49.0M$49.0MFY2022FY2023: $89.1M$89.1MFY2023FY2024: $139.9M$139.9MFY2024FY2025: $134.5M$134.5MFY2025

From RXST's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
5firms
1 Buy3 Hold1 Sell
Each firm's latest rating on RXST in the past 90 days
Average 12-month target
$6.45
▲ 33.5% upside

Based on 5 analysts who set a price target on RXST in the past 90 days. The average target is $6.45, with a high of $8.00 and a low of $5.50, compared with the last close of $4.83.

Low $5.50Avg $6.45High $8.00
Blue marker: last close $4.83
Highest target$8.00
Average target$6.45
Lowest target$5.50
Latest rating changes
Piper SandlerMaintained
Nov 4Hold$8
Wells FargoMaintained
Nov 4Hold$6
NeedhamTarget lowered
Nov 4Buy$11 → $7
JefferiesMaintained
Sep 22Hold$5.75
B of A SecuritiesTarget lowered
Sep 22Sell$6.50 → $5.50
DateFirmActionRatingPrice target
Nov 4Piper SandlerMaintainedHold$8
Nov 4Wells FargoMaintainedHold$6
Nov 4NeedhamTarget loweredBuy$11 → $7
Sep 22JefferiesMaintainedHold$5.75
Sep 22B of A SecuritiesTarget loweredSell$6.50 → $5.50
Loading…

Technical Analysis

RXST · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 2% below its 20 day and 3% below its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the swing low (Jul 7) at $4.81, and the nearest resistance the Pivot at $4.94.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 7.7%/day
Key levels
$13.2252 week high+173.7%
$6.10200 day average+26.3%
$5.50100 day average+13.9%
$5.18Pivot R1+7.2%
$4.9950 day average+3.3%
$4.98Swing high (Oct 12)+3.1%
$4.9520 day average+2.5%
$4.94Pivot+2.3%
$4.83Last close
$4.81Swing low (Jul 7)−0.4%
$4.59Pivot S1−5.0%
$4.1152 week low−14.9%
Indicators
RSI (14)46.54Middle of its rangeNeutral
MACD0.04Above its signal lineBullish
Stochastic68.7Middle of its rangeNeutral
ADX (14)23.1Weak trend
Williams %R-52.5Oversold below −80, overbought above −20Neutral
CCI (20)-3.6Oversold below −100, overbought above 100Neutral
Rate of change+5.2%Change over 10 sessionsBullish
ATR (14)$0.37Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RXST

What happened before

See how RXST did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RXST usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RXST has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RXST in the last 90 days.

Loading…

See today’s whale options flow across the market →

RXST Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●72 buying vs 79 selling
  • ▼Held by funds -12.6 pts
  • ▲Funds holding +5
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding156151+3.3%
In funds' top 10110.0%
Held by funds86.3%98.8%−12.6 pts
New / increased25 / 4725 / 72−25.8%
Reduced / sold out59 / 2035 / 36+11.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RXST institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RXST is in one of them and how their past RXST trades turned out.

RXST in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RXST in an article yet. Here's the latest on the wider market.

About RxSight

RxSight is a medical technology company based in Aliso Viejo, California. It makes a premium cataract lens system that lets eye surgeons adjust a patient's vision after surgery. The system includes an implantable lens and a light device that uses ultraviolet light to change the lens's focusing power. Its customers are eye surgeons and ophthalmology practices, mainly in the United States, and its end users are patients undergoing cataract surgery.

Headquarters
Aliso Viejo, CA